The pathophysiological role of calsequestrin for the development of cardiac hypertrophy
The pathophysiological role of calsequestrin for the development of cardiac hypertrophy
批准号:
07670754
负责人:
ARAI Masashi
金额:
$1.6万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1995
资助国家:
日本
项目状态:
已结题
起止时间:
1995 至 1996
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study was to clarify the role of calsequestrin, the major Ca2+ binding protein located in the sarcoplasmic reticulum, for the development of cardiac hypertrophy. We measured the Ca2+ storage capacity of calsequestrin arid the Ca2+ uptake capacity of sarcoplasmic reticulum Ca2+-ATPase using transgenic mice that overexpress sodium/proton antiporter gene as a model of cardiac hypertrophy. These mice develop hypertension and subsequent cardiac hypertrophy under high salt loading condition. Our experimental results suggest that :1) Ca2+ storage capacity as well as Ca2+ uptake function is the important determinant of cardiac mechanical properties. Both functions are diminished in hypertrophied hearts, which will significantly contribute the decreased heart rate and slowed relaxation and contraction observed in hemodynamically overloaded hearts.2) Although the Ca2+ storage function of calsequestrin was decreased in hypertrophied hearts, the expression level of calsequestrin mRNA remained unaltered. Translational modification of calsequestrin gene may explain the discrepancy between the function and the mRNA expression level.3) It has been known that Ca2+ is a second messenger which induces cellular proliferation and gene transcription. The Ca2+ uptake and storage capacity was diminished in the examined hearts. Therefore, the Ca2+ transported by calsequestrin and Ca2+-ATPase may not function as a cellular hypertrophic signal, but merely as a regulator of cardiac function.Recently, it was reported that calsequestrin contacts with ryanodine receptor, the major Ca2+ release channel of sarcoplasmic reticulum. Future studies should be aimed to measure calcium release activity simultaneously and clarify whether calsequestrin has a regulatory function for Ca2+ release. In addition, the transcriptional and translational regulation of calsequestrin gene should also be determined.
期刊论文(15)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
新井昌史: "心不全の遺伝子治療" 臨床医. 23. 96-97 (1997)
Masashi Arai:“心力衰竭的基因治疗”临床医生。23. 96-97 (1997)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Arai M,Yoguchi A,Iso T,Takahashi T,Imai S,Murata K,Suzuki T.: "Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy" Am J Physiol 268 (Heart Circ Physiol 37). 268. H2084-H2091 (1995)
Arai M、Yoguchi A、Iso T、Takahashi T、Imai S、Murata K、Suzuki T.:“内皮素 1 及其结合位点在压力超负荷心脏肥大中上调”Am J Physiol 268(Heart Circ Physiol 37)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Arai M,Suzuki T,Nagai R.: "Sarcoplasmic reticulum genes are up-regulated in mild cardiac hypertrophy but down-regulated in severe cardiac hypertrophy induced by pressure overload" J Moll Cell Cardiol. 28. 1583-1590 (1996)
Arai M、Suzuki T、Nagai R.:“肌浆网基因在轻度心脏肥大中上调,但在压力超负荷引起的重度心脏肥大中下调”J Moll Cell Cardiol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
新井昌史: "心不全の遺伝子治療の可能性" 治療学. 30. 104-108 (1996)
Masashi Arai:“基因治疗心力衰竭的可能性”《治疗学》30. 104-108 (1996)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
新井昌史: "カルディオトロフィン-1" 内分泌・糖尿病科. 3. 439-444 (1996)
Masashi Arai:“Cardiotropin-1”内分泌和糖尿病系 3. 439-444 (1996)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 15 条
Analysis of Corporate Strategy and Effects on Competition through Consortium Based Standardization
-
批准号:21830121
-
项目类别:Grant-in-Aid for Research Activity Start-up
-
资助金额:$1.14万
-
财政年份:2009
-
负责人:ARAI Masashi
-
依托单位:
Development of novel therapeutic strategy for heart failure by improving Ca2+ transport function of sarcoplasmic reticulum
-
批准号:15590717
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2003
-
负责人:ARAI Masashi
-
依托单位:
Development of novel heart failure therapy by using gene transfer into cardiac myocytes
-
批准号:13832002
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.37万
-
财政年份:2001
-
负责人:ARAI Masashi
-
依托单位:
Transcriptional regulation of the SERCA2 gene during the development of heart failure
-
批准号:11838001
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:1999
-
负责人:ARAI Masashi
-
依托单位:
Analyses of transcriptional regulation and signal transduction of sarcoplasmic reticulum Ca^<2+>
-
批准号:09670692
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.11万
-
财政年份:1997
-
负责人:ARAI Masashi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Calcium/NFAT/GLUT3通路调控糖酵解代谢在CAR-T细胞耗竭中的作用和机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:张明明
-
依托单位:
钙信号负向调节因子IRBIT抑制肝癌细胞恶性生物学行为的分子机制研究
-
批准号:31960151
-
项目类别:地区科学基金项目
-
资助金额:40.0万元
-
批准年份:2019
-
负责人:徐靖宇
-
依托单位:
基于钙信号特征机制的肿瘤转移调控研究
-
批准号:31970729
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:魏朝亮
-
依托单位:
一种拟南芥IP3结合蛋白作用机制及功能研究
-
批准号:31970723
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2019
-
负责人:韩生成
-
依托单位:
miR-30调控Calcium/Calcineurin通路在慢性肾脏病心肌保护中的作用
-
批准号:81670699
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:郑春霞
-
依托单位:
钙磷基纳米粒子的分布降解及其成骨系细胞响应机制研究
-
批准号:81171682
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:陈大福
-
依托单位:
TRPCs,STIMs及Orais在钙敏感受体介导钙内流及一氧化氮生成中作用和机制研究
-
批准号:31160239
-
项目类别:地区科学基金项目
-
资助金额:53.47万元
-
批准年份:2011
-
负责人:何芳
-
依托单位:
缺氧状况下ATP对血管的调节作用
-
批准号:81041100
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2010
-
负责人:顾雨春
-
依托单位:
水稻OsCAS(Calcium-sensing Receptor)基因的功能分析
-
批准号:30900771
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2009
-
负责人:赵昕
-
依托单位:
小胶质细胞转核P2X7受体介导的生物学效应的研究
-
批准号:30970918
-
项目类别:面上项目
-
资助金额:33.0万元
-
批准年份:2009
-
负责人:向正华
-
依托单位: